What is HC Wainwright’s Estimate for AMLX FY2025 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($1.76) per share for the year, down from their prior forecast of ($1.01). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.59) EPS and FY2028 earnings at ($1.16) EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter.

AMLX has been the subject of several other reports. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Four analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Amylyx Pharmaceuticals Stock Up 7.2 %

Amylyx Pharmaceuticals stock opened at $3.87 on Monday. The stock has a 50-day simple moving average of $3.53 and a 200 day simple moving average of $3.89. Amylyx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $7.27. The stock has a market capitalization of $265.28 million, a price-to-earnings ratio of -1.01 and a beta of -0.51.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in AMLX. Blue Trust Inc. raised its stake in Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after acquiring an additional 4,883 shares during the period. Fox Run Management L.L.C. bought a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. Alpine Global Management LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. RPO LLC bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth $46,000. Finally, EntryPoint Capital LLC bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth $53,000. Institutional investors own 95.84% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Justin B. Klee sold 7,471 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the sale, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares of the company’s stock, valued at approximately $11,108,327.09. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,169 shares of company stock valued at $97,274 in the last quarter. 11.70% of the stock is currently owned by insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.